Bristol-Myers Squibb Company (BMY) said Thursday that it has discontinued development of BMS-986094, a nucleotide polymerase inhibitor that was in Phase II development for the treatment of hepatitis C.
The company had suspended the Phase II study on August 1, after an initial case of heart failure which subsequently resulted in death. Nine patients have been hospitalized to date.
Bristol-Myers is working in close collaboration with the FDA and clinical study investigators to conduct ongoing, comprehensive assessments and close follow-up of all BMS-986094 study patients.
While the cause of these unexpected events, which involve heart and kidney toxicity, has not been definitively established, the company has determined that it is in the best interest of patients to halt development of BMS-986094.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.